Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 115 Show results per page	View Search Criteria \| Help With Results


1.		Treatment of Acute Myeloblastic Leukemia in Younger Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Biomarker/Laboratory analysis, Treatment				Closed				65 and under				Other				AML99<=65 años NCT00390715


2.		Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase IV				Treatment				Completed				75 and under				Other				Pethema LPA-99 protocol NCT00465933

Last Modified: 12/1/1998


3.		Phase II/III Randomized Study of Monoclonal Antibody HuM195 As Maintenance Therapy in Elderly Patients with Acute Myeloid Leukemia in Complete Remission Following Chemotherapy (Summary Last Modified 12/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				60 and over				Pharmaceutical / Industry				PDL-3-251 MSKCC-93131, NCI-V94-0469

Last Modified: 11/1/1997


4.		Phase II/III Pilot Treatment of Pediatric Non-B, Non-T ALL in First Marrow Relapse (SIMAL #8): Intensive Re-Induction and Reconsolidation Chemotherapy with Subsequent Myeloablative Chemoradiotherapy and Rescue with Either Allogeneic or In Vitro-Purged Autologous Marrow (Summary Last Modified 11/97)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Completed				under 21 at relapse				NCI				POG-9410 POG-SIMAL-8, POG-9410


5.		Phase II/III Comparison of Single-agent Chemotherapy with Idarubicin vs Menogaril vs 4'-Epiadriamycin vs Standard Chemotherapy with CAV (CTX/ADR/VCR) in Patients with Extensive Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Closed				18 and over				NCI				EST-1586 EST-1586

Last Modified: 4/10/2008


6.		Phase III Randomized Study of Induction and Intensification Regimens for Childhood Acute Myeloid Leukemia: IDA vs DNR with ARA-C/VP-16 for Induction in All Patients and Intensification with High-Dose ARA-C/DHAD (HAM) Before vs After Consolidation in High-Risk Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				under 17								GER-GPOH-AML-BFM-93 EU-93008

Last Modified: 5/4/2007 First Published: 1/1/1994


7.		Phase III Randomized Study of Intensive Therapy for Acute Myelogenous Leukemia (the AML 10 Protocol): IDA vs DHAD vs DNR with ARA-C/VP-16 for Induction and Intermediate-Dose ARA-C for Consolidation Followed by AlBMT vs AuBMT vs PBSC (Summary Last Modified 08/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to 60								EORTC-06931 NCT00002549

Last Modified: 5/4/2007


8.		Phase III Randomized Study of Sequential Treatment with 3 Noncross-Resistant Chemotherapy Combinations or Standard Chemotherapy for Poor-Prognosis Intermediate Grade and Immunoblastic non-Hodgkin's Lymphoma: IDA/CDDP/ARA-C/MePRDL, IDA/VCR/BLEO/CTX/MePRDL, and IFF/DHAD/VP-16 vs Standard CHOP (Summary Last Modified 09/2000)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				over 15				NCI				MDA-DM-94017 NCI-T94-0040D, NCT00002565, T94-0040

Last Modified: 5/24/2006


9.		Phase III Randomized Study of Bone Marrow Transplantation vs Prolonged Intensive Chemotherapy Following Remission Re-Induction after Early First Marrow Relapse in Children with Acute Lymphocytic Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				at least 1 + under 20 at diag.				NCI				CCG-1941 CCG-1941

Last Modified: 2/26/2008 First Published: 6/1/1995


10.		Phase III Randomized Study of Two Induction Courses That Include Daunorubicin vs Mitoxantrone and Filgrastim (G-CSF) vs Placebo, Followed By MACE (Amsacrine, Cytarabine, and Etoposide), Then Bone Marrow Transplantation (BMT) vs MidAC (Mitoxantrone and Cytarabine) vs ICE (Idarubicin, Cytarabine, and Etoposide) Followed By BMT vs ICE Followed By MidAC in Patients With Acute Myeloid Leukemia

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				15 to physiologic 59				Other				MRC-LEUK-AML12 EU-95001, NCT00002658

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute